ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor

Abstract

The TMPRSS2:ERG gene fusion is common in androgen receptor (AR) positive prostate cancers, yet its function remains poorly understood. From a screen for functionally relevant ERG interactors, we identify the arginine methyltransferase PRMT5. ERG recruits PRMT5 to AR-target genes, where PRMT5 methylates AR on arginine 761. This attenuates AR recruitment and transcription of genes expressed in differentiated prostate epithelium. The AR-inhibitory function of PRMT5 is restricted to TMPRSS2:ERG-positive prostate cancer cells. Mutation of this methylation site on AR results in a transcriptionally hyperactive AR, suggesting that the proliferative effects of ERG and PRMT5 are mediated through attenuating AR's ability to induce genes normally involved in lineage differentiation. This provides a rationale for targeting PRMT5 in TMPRSS2:ERG positive prostate cancers. Moreover, methylation of AR at arginine 761 highlights a mechanism for how the ERG oncogene may coax AR towards inducing proliferation versus differentiation.

Article and author information

Author details

  1. Zineb Mounir

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Joshua M Korn

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Thomas Westerling

    Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Fallon Lin

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Christina A Kirby

    Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Markus Schirle

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Gregg McAllister

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Greg Hoffman

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Nadire Ramadan

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Anke Hartung

    Genomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Yan Feng

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. David Randal Kipp

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Christopher Quinn

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Michelle Fodor

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Jason Baird

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Marie Schoumacher

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Ronald Meyer

    Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. James Deeds

    Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  19. Gilles Buchwalter

    Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. Travis Stams

    Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Nicholas Keen

    Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. William R Sellers

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  23. Myles Brown

    Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  24. Raymond A Pagliarini

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    For correspondence
    raymond.pagliarini@novartis.com
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Mounir et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,075
    views
  • 1,052
    downloads
  • 63
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zineb Mounir
  2. Joshua M Korn
  3. Thomas Westerling
  4. Fallon Lin
  5. Christina A Kirby
  6. Markus Schirle
  7. Gregg McAllister
  8. Greg Hoffman
  9. Nadire Ramadan
  10. Anke Hartung
  11. Yan Feng
  12. David Randal Kipp
  13. Christopher Quinn
  14. Michelle Fodor
  15. Jason Baird
  16. Marie Schoumacher
  17. Ronald Meyer
  18. James Deeds
  19. Gilles Buchwalter
  20. Travis Stams
  21. Nicholas Keen
  22. William R Sellers
  23. Myles Brown
  24. Raymond A Pagliarini
(2016)
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor
eLife 5:e13964.
https://doi.org/10.7554/eLife.13964

Share this article

https://doi.org/10.7554/eLife.13964

Further reading

    1. Cancer Biology
    2. Cell Biology
    Kourosh Hayatigolkhatmi, Chiara Soriani ... Simona Rodighiero
    Tools and Resources

    Understanding the cell cycle at the single-cell level is crucial for cellular biology and cancer research. While current methods using fluorescent markers have improved the study of adherent cells, non-adherent cells remain challenging. In this study, we addressed this gap by combining a specialized surface to enhance cell attachment, the FUCCI(CA)2 sensor, an automated image analysis pipeline, and a custom machine learning algorithm. This approach enabled precise measurement of cell cycle phase durations in non-adherent cells. This method was validated in acute myeloid leukemia cell lines NB4 and Kasumi-1, which have unique cell cycle characteristics, and we tested the impact of cell cycle-modulating drugs on NB4 cells. Our cell cycle analysis system, which is also compatible with adherent cells, is fully automated and freely available, providing detailed insights from hundreds of cells under various conditions. This report presents a valuable tool for advancing cancer research and drug development by enabling comprehensive, automated cell cycle analysis in both adherent and non-adherent cells.

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark LaBarge
    Research Article

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.